UNITUXIN (dinutuximab)
ANTINEOPLASTIC - ANTI-GD2 GANGLIOSIDE MONOCLONAL ANTIBODY · HIGH-RISK NEUROBLASTOMA
UNITED THERAP
Drug class
Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody
Antineoplastic anti-GD2 ganglioside monoclonal antibodies are a targeted class of immunotherapeutic agents designed to direct the host immune system against malignant cells expressing disialoganglioside GD2. Read more about Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody
2 drugs in this class 2 manufacturers
Drugs in Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody
DANYELZA (naxitamab-gqgk)
ANTINEOPLASTIC - ANTI-GD2 GANGLIOSIDE MONOCLONAL ANTIBODY · HIGH-RISK NEUROBLASTOMA IN BONE OR BONE MARROW
Y-MABS THERAPEU
Filter & compare in the drug finder →
Opens the drug finder with Antineoplastic - Anti-GD2 Ganglioside Monoclonal Antibody preselected. Add indication or manufacturer filters there.
Antineoplastic anti-GD2 ganglioside monoclonal antibodies are a targeted class of immunotherapeutic agents designed to direct the host immune system against malignant cells expressing disialoganglioside GD2.
By selectively binding to GD2 molecules—which are densely expressed on neuroectodermal tumors but minimally present on normal tissues—these antibodies destroy cancer cells primarily through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity.
Clinically, agents in this class, such as dinutuximab and naxitamab, are primarily indicated for the treatment of high-risk or relapsed/refractory neuroblastoma, often administered in multimodality regimens alongside immune-enhancing cytokines or adjuvant therapies.
-
cancer.gov
Antineoplastic anti-GD2 ganglioside monoclonal antibodies are a targeted class of immunotherapeutic agents designed to direct the host immune system against malignant cells expressing disialoganglioside GD2 By selectively binding to GD2 molecules—which are densely expressed on neuroectodermal tumors but minimally present on normal tissues—these antibodies destroy cancer cells primarily through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity
-
nih.gov
Antineoplastic anti-GD2 ganglioside monoclonal antibodies are a targeted class of immunotherapeutic agents designed to direct the host immune system against malignant cells expressing disialoganglioside GD2 By selectively binding to GD2 molecules—which are densely expressed on neuroectodermal tumors but minimally present on normal tissues—these antibodies destroy cancer cells primarily through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity Clinically, agents in th...
-
selleckchem.com
By selectively binding to GD2 molecules—which are densely expressed on neuroectodermal tumors but minimally present on normal tissues—these antibodies destroy cancer cells primarily through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity
-
rxlist.com
Clinically, agents in this class, such as dinutuximab and naxitamab, are primarily indicated for the treatment of high-risk or relapsed/refractory neuroblastoma, often administered in multimodality regimens alongside immune-enhancing cytokines or adjuvant therapies
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.